Edition:
United Kingdom

Sunesis Pharmaceuticals Inc (SNSS.OQ)

SNSS.OQ on NASDAQ Stock Exchange Capital Market

2.40USD
18 Jul 2018
Change (% chg)

$-0.01 (-0.41%)
Prev Close
$2.41
Open
$2.39
Day's High
$2.40
Day's Low
$2.37
Volume
10,539
Avg. Vol
56,639
52-wk High
$7.68
52-wk Low
$1.84

Summary

Name Age Since Current Position

James Young

2009 Non-Executive Independent Chairman of the Board

Dayton Misfeldt

44 2018 Interim Chief Executive Officer, Director

William Quinn

2017 Chief Financial Officer, Senior Vice President - Finance and Corporate Development

Adam Craig

51 2012 Executive Vice President - Development, Chief Medical Officer

Stephen Ketchum

50 2012 Director

H. Ward Wolff

69 2018 Director

Steve Carchedi

55 2013 Independent Director

Matthew Fust

53 2005 Independent Director

Homer Pearce

62 2006 Independent Director

David Stump

68 2006 Independent Director

Biographies

Name Description

James Young

Dr. James W. Young, Ph.D., is Non-Executive Independent Chairman of the Board of Sunesis Pharmaceuticals, Inc., since April 3, 2009. From May 2000 to November 2003, Dr. Young served as Chief Executive Officer. In April 2006, he joined 5AM Ventures, a venture capital firm, as a Venture Partner. From September 1995 to March 2000, Dr. Young served as Vice President of Research, as Senior Vice President, Research and Development, and as Group Vice President at ALZA Corporation, a pharmaceutical company. From September 1992 to August 1995, Dr. Young served as Senior Vice President for Business Development and as President of the Pharmaceuticals Division of Affymax, N.V., a biopharmaceutical company. From September 1987 to August 1992, he served as Senior Vice President for Business Development and as Senior Vice President and General Manager of the Pharmaceuticals Division at Sepracor Inc., a pharmaceutical company. Dr. Young also served as a director of Corixa Corporation, a biopharmaceutical company, from 2000 to July 2005. Dr. Young also serves as a member of the board of directors of Pearl Therapeutics, Inc., a private company. Dr. Young holds a B.S. in Chemistry from Fordham University and a Ph.D. in Organic Chemistry from Cornell University.

Dayton Misfeldt

Mr. Dayton Misfeldt re designated as Interim Chief Executive Officer, Director of the Company effective January 2018. He has served as a member of the Board since 2009. Mr. Misfeldt is a Managing Director of Bay City Capital LLC, a venture capital firm, and focuses on biopharmaceutical investment opportunities. Prior to joining Bay City Capital in May 2000, Mr. Misfeldt was a Vice President at Roth Capital Partners where he worked as a sell-side analyst covering the biopharmaceutical industry. Mr. Misfeldt has also worked as a Project Manager at LifeScience Economics. Mr. Misfeldt received a B.A. in Economics from the University of California, San Diego.

William Quinn

Mr. William Quinn is Chief Financial Officer, Senior Vice President - Finance and Corporate Development of the Company. Prior to joining Sunesis, Mr. Quinn was President and Chief Executive Officer of Bullet Biotechnology, a company developing immunotherapies for cancer and autoimmune diseases, which he founded in 2011. At Bullet Bio, Willie partnered with multiple biopharma companies and universities, raised multiple round of equity and convertible debt funding, and oversaw early development of several products. From 2003 to 2011, Mr. Quinn held various management positions at Jazz Pharmaceuticals, helping the company grow from a four-person startup to a successful commercial specialty pharmaceutical company. During his tenure at Jazz, Mr. Quinn managed investor relations, partnering, mergers and acquisitions, and strategic planning activities. He began his career in the life science industry at Novation Biosciences. Willie also has prior investing experience from his time as an Associate Partner at Mobius Venture Capital. Mr. Quinn obtained his MBA from the Stanford Graduate School of Business and also earned an MA and BA from Stanford University.

Adam Craig

Dr. Adam R. Craig, M.D., Ph.D., is an Executive Vice President - Development, Chief Medical Officer of Sunesis Pharmaceuticals, Inc., since March 1, 2012. From September 2007 until December 2011, Dr. Craig served as Chief Medical Officer of ChemGenex Pharmaceuticals Ltd., a biotechnology company focused on the development of novel therapeutic agents for the treatment of cancer, and in similar roles following the acquisition of ChemGenex by Cephalon, Inc. in July 2011, and the acquisition of Cephalon, Inc. by Teva Pharmaceutical Industries Ltd. in October 2011. From December 2011 until joining the Company, Dr. Craig served as a consultant to Teva Pharmaceutical Industries Ltd. Before joining ChemGenex, he was founding Chief Medical Officer at Innovive Pharmaceuticals, Inc., a hematology-focused company. Prior to joining Innovive, Dr. Craig held positions of increasing responsibility at ArQule Inc., Ilex Oncology Inc., and Antisoma plc. Dr. Craig received his medical qualifications from London University, a Ph.D. in molecular medicine from the University of Leeds, and an M.B.A. from the Open Business School in the United Kingdom. Dr. Craig is a member of the Royal College of Pediatrics and Child Health Physicians (UK) and undertook post-graduate training in pediatrics and pediatric oncology. He also currently serves as a member of the Commercialization Review Council for the Cancer Prevention Research Institute of Texas, a fund for cancer research and prevention programs and services.

Stephen Ketchum

Dr. Stephen B. Ketchum, Ph.D., is Director of Sunesis Pharmaceuticals, Inc. He served as Senior Vice President, Research and Development from June 2008 to February 2012. In February 2012, Dr. Ketchum accepted the position of President of Research and Development, Senior Vice President at Amarin Corporation plc, a biopharmaceutical company, and concurrently transitioned from his executive role to a member of the Board. From May 2005 to May 2008, Dr. Ketchum served as Senior Vice President, Research & Development and Medical Affairs of Reliant Pharmaceuticals, Inc., a pharmaceutical company, which was acquired by GlaxoSmithKline in 2007. From June 2002 to April 2005, Dr. Ketchum served as Senior Vice President, Operations and Regulatory Affairs for IntraBiotics Pharmaceuticals, Inc. Dr. Ketchum also held positions at ALZA Corporation from November 1994 to May 2002, most recently as Senior Director, Regulatory Affairs. Dr. Ketchum earned a Ph.D. in Pharmacology from University College London (funded by the Sandoz Institute for Medical Research) and a B.S. in Biological Sciences from Stanford University.

H. Ward Wolff

Mr. H. Ward Wolff is Director of the company. He currently serves as a member of the boards of directors of Portola Pharmaceuticals Inc. and Calithera Biosciences, Inc. Mr. Wolff served as Executive Vice President and Chief Financial Officer of Sangamo Therapeutics, Inc. from 2007 until his retirement in March 2017. Prior to Sangamo, Mr. Wolff served as Senior Vice President, Finance and Chief Financial Officer of Nuvelo, Inc. until its restructuring in August 2007 and, before that, he was Chief Financial Officer and Senior Vice President, Finance, of Abgenix, Inc. until April 2006 when Abgenix merged with Amgen Inc. Prior to joining Abgenix, Mr. Wolff held financial management positions in both public and private emerging growth companies. He began his career with Price Waterhouse, where he held a number of positions as a certified public accountant, including Senior Audit Manager. Mr. Wolff received a B.A. degree in Economics from the University of California at Berkeley and an M.B.A. degree from Harvard Business School.

Steve Carchedi

Mr. Steve R. Carchedi is an Independent Director of Sunesis Pharmaceuticals, Inc. Currently, Mr. Carchedi serves as the President, Commercial Operations for Mallinckrodt Specialty Pharmaceuticals, the Pharmaceuticals business of Covidien plc. Mr. Carchedi brings more than 30 years of commercial industry experience focused in Oncology, Neurology, Urology, Endocrinology and Cardiology. Previously, he served as Chief Marketing Officer for General Electric (GE) Healthcare-MDx where he was responsible for worldwide marketing for GE’s Medical Diagnostics business. Prior to joining GE Healthcare, Mr. Carchedi held senior commercial leadership positions at Endo Pharmaceuticals, Enzon Pharmaceuticals and McNeil Specialty Pharmaceuticals, a subsidiary of Johnson & Johnson. Mr. Carchedi also held the position of Global Marketing Leader for Johnson & Johnson Oncology, where he led the worldwide product launch of VELCADE® (bortezomib). Before joining Johnson & Johnson, Mr. Carchedi played a key role in commercializing a number of oncology products, including GEMZAR® (gemcitabine) at Eli Lilly & Company, as well as TAXOL® (paclitaxel) and PARAPLATIN® (carboplatin) at Bristol Myers Squibb. In addition to his industry experience, Mr. Carchedi currently serves on the Board of Directors of BioNumerick Pharmaceuticals, on the Strategic Advisory Board for PCAsso Diagnostics LLC, and as Co-Chair of BioNJ’s Personalized Medicine & Diagnostics Committee. Mr. Carchedi received a B.S. in Marketing from West Chester University and an MBA in Marketing from Drexel University.

Matthew Fust

Mr. Matthew K. Fust is an Independent Director of Sunesis Pharmaceuticals, Inc., since May 2005. He has been Executive Vice President and Chief Financial Officer at Onyx Pharmaceuticals, Inc., a biopharmaceutical company, since January 2009. Prior to joining Onyx, Mr. Fust was Executive Vice President and Chief Financial Officer at Jazz Pharmaceuticals, Inc., a pharmaceutical company, which he joined in May 2003. From May 2002 to May 2003, Mr. Fust was Chief Financial Officer at Perlegen Sciences, Inc., a biotechnology company. From June 1996 to January 2002, Mr. Fust was with ALZA Corporation, first as Controller and then as Chief Financial Officer. Mr. Fust holds a B.A. in Accounting from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business.

Homer Pearce

Dr. Homer L. Pearce, Ph.D., is an Independent Director of Sunesis Pharmaceuticals, Inc., since June 29, 2006. He served in various capacities at Eli Lilly & Company between 1979 and March 2006, including Vice President, Cancer Research and Clinical Investigation from 1994 to 2002 and Distinguished Research Fellow, Cancer Research, Lilly Research Laboratories from 2002 to March 2006. He is a member of the American Association for Cancer Research, the American Chemical Society and the American Association for the Advancement of Science. Dr. Pearce holds a B.S. from Texas A&M University and a Ph.D. in Organic Chemistry from Harvard University.

David Stump

Dr. David C. Stump, M.D., is an Independent Director of Sunesis Pharmaceuticals, Inc., since June 29, 2006. He was most recently Executive Vice President, Research and Development, at Human Genome Sciences, Inc., a biopharmaceutical company, serving there from November 1999 until December 2012. From December 2003 to May 2007, Dr. Stump served as Executive Vice President of Drug Development at Human Genome Sciences and, from November 1999 to December 2003, as its Senior Vice President, Drug Development. Prior to joining Human Genome Sciences, Dr. Stump held roles of increasing responsibility at Genentech, Inc., a biopharmaceutical company, from 1989 to 1999, including Vice President, Clinical Research and Genentech Fellow. Prior to joining Genentech, Dr. Stump was an Associate Professor of Medicine and Biochemistry at the University of Vermont. Dr. Stump is a member of the board of directors of Dendreon Corporation, a biotechnology company, and a member of the board of trustees of Earlham College. Dr. Stump holds an A.B. from Earlham College and an M.D. from Indiana University and did his residency and fellowship training in internal medicine, hematology, oncology and biochemistry at the University of Iowa.

Basic Compensation